Med (New York, N.Y.)HumansLeukemiaLymphocyticChronicB-Cell
Ramping up the express stairs: Lisaftoclax in CLL.
Nawar Maher, Gianluca Gaidano
Published: 202510.1016/j.medj.2025.100921
Abstract
Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy…
Preview only. Read the full abstract at the source